Jenburkt Pharmaceuticals Ltd. reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2016. For the quarter, the company reported net sales/income from operations (net of excise duty) of INR 248.505 million against INR 240.610 million a year ago. Profit from operations before other income, finance costs & exceptional items was INR 39.165 million against INR 43.727 million a year ago. Profit from ordinary activities before tax was INR 44.846 million against INR 49.639 million a year ago. Net profit for the period was INR 29.511 million or INR 6.35 per basic and diluted share before and after extraordinary items against INR 35.025 million or INR 7.53 per basic and diluted share before and after extraordinary items a year ago. For the nine months, the company reported net sales/income from operations (net of excise duty) of INR 756.956 million against INR 710.298 million a year ago. Profit from operations before other income, finance costs & exceptional items was INR 127.145 million against INR 123.080 million a year ago. Profit from ordinary activities before tax was INR 144.351 million against INR 139.073 million a year ago. Net profit was INR 99.306 million or INR 21.36 per basic and diluted share before and after extraordinary items against INR 94.853 million or INR 20.40 per basic and diluted share before and after extraordinary items a year ago.